# SQZ Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sqz-biotech

- Industry: Biotechnology
- Headquarters: Watertown, US
- Website: www.sqzbiotech.com
- Total disclosed funding: $234M
- Latest round: Series D (Dec 19, 2019)
- Investors on record: 13

## About

SQZ Biotech, Inc. is a US-based company specializing in innovative cell therapy platforms that create targeted therapies for various diseases, particularly cancer and autoimmune conditions.Founded in 2013 and headquartered in Watertown, US, SQZ Biotech, Inc. focuses on developing cell therapies that leverage cellular properties to treat diseases. The company has engaged in 11 deals, with its most recent funding round occurring on October 29, 2020, when it raised USD 2.00 mn in a Grant from The National Institutes of Health as part of its total amount raised of USD 60.00 mn. The company’s CEO and founder, Armon Sharei, has a history of leadership in biotechnology ventures.SQZ Biotech develops cell-based therapies utilizing proprietary technology to enhance the immune response against tumors while minimizing harm to healthy tissue. They primarily cater to biotechnology and pharmaceutical companies, providing advanced cell therapies for integration into their product pipelines and conducting business in North America and Europe.In 2022, SQZ Biotech generated a revenue of USD 21.48 mn, with an EBITDA loss of USD 69.00 mn, highlighting the company's focus on long-term growth in the biotech sector through strategic collaborations and partnerships.SQZ Biotech plans to enhance its multi-functional cell therapy pipeline through recent funding. Notably, the company raised USD 60.00 mn in February 2021, intending to utilize these funds for the development of upcoming product offerings. The company is also targeting expansion into additional geographic regions, with a focus on markets in Europe and Asia by 2024.

## Funding rounds

- Series D, Dec 19, 2019, $66M — Temasek Holdings, Polaris Partners, Invus [DUP], +ND Capital, GV, Illumina Ventures, JDRF T1D Fund
- Series C, Aug 14, 2018, $72M — Viva Ventures Biotech
- Series C, May 11, 2018, $71M — Polaris Partners, Invus [DUP], +ND Capital, GV, Bridger Capital, Illumina Ventures, JDRF T1D Fund, Quark Venture, Everblue Management, Orient Life
- Series B, Dec 1, 2016, $4M — GV, Quark Venture
- Series B, Sep 19, 2016, $16M — Polaris Partners, +ND Capital
- Series A, Jun 30, 2015, $5.1M — Polaris Partners, 20/20 HealthCare Partners

## Investors

- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series A, Series B, Series C, Series D
- 20/20 HealthCare Partners (https://capitalatlas.ai/funds/20-20-healthcare-partners) — Series A
- +ND Capital (https://capitalatlas.ai/funds/nd-capital) — Series B, Series C, Series D
- GV (https://capitalatlas.ai/funds/gv) — Series B, Series C, Series D
- Quark Venture (https://capitalatlas.ai/funds/quark-venture) — Series B, Series C
- Invus [DUP] — Series C, Series D
- Bridger Capital — Series C
- Illumina Ventures (https://capitalatlas.ai/funds/illumina-ventures) — Series C, Series D
- JDRF T1D Fund (https://capitalatlas.ai/funds/jdrf-t1d-fund) — Series C, Series D
- Everblue Management — Series C
- Orient Life — Series C
- Viva Ventures Biotech (https://capitalatlas.ai/funds/viva-ventures-biotech) — Series C
- Temasek Holdings — Series D